The inhibition of extended spectrum β-lactamases: Hits and leads

Current Medicinal Chemistry

Volumn 21, Issue 12, 2014, Pages 1405-1434

  Farina, Davide ^a   Spyrakis, Francesca ^a   Venturelli, Alberto ^b   Cross, Simon ^c   Tondi, Donatella ^a   Costi, Maria Paola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Tydock Pharma   (Italy)

^c Molecular Discovery Limited   (United Kingdom)

Author keywords

Carbapenemase; Extended spectrum lactamases; Molecular interaction fields; Resistance; lactam antibiotics; lactamase binding site; lactamase inhibitors

Indexed keywords

AMPICILLIN; AVIBACTAM; AZTREONAM; BENZO[B]THIEN 2 YL BORONIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BIAPENEM; BORONIC ACID DERIVATIVE; CARBAPENEMASE; CEFALOTIN; CEFOTAXIME; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; CYCLOBUTANONE DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; FROPENEM; IMIPENEM; LATAMOXEF; LIGAND; MEROPENEM; METICILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PENICILLIN G; SULBACTAM; SULFONAMIDE; TAZOBACTAM; THIENAMICYN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL STRAIN; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG RESEARCH; DRUG STRUCTURE; ENZYME INHIBITION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; NONHUMAN; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS;

BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; PROTEIN INTERACTION DOMAINS AND MOTIFS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899830655     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660323     Document Type: Review

References (246)

1. Babic, M.; Hujer, A.M.; Bonomo, R.A. What's new in antibiotic resistance? Focus on beta-lactamases. Drug. Resist. Updat., 2006, 9(3), 142-156.
2. Drawz, S.M.; Bonomo, R.A. Three decades of beta-lactamase inhibitors. Clin. Microbiol. Rev., 2010, 23(1), 160-201.
3. Ambler, R.P. The structure of beta-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 1980, 289(1036), 321-331.
4. Abraham, E.P.; Chain, E. An Enzyme from Bacteria able to destroy Penicillin. Nature, 1940, 146, 837-837.
5. Kirby, W.M. Extraction of a Highly Potent Penicillin Inactivator from Penicillin Resistant Staphylococci. Science, 1944, 99(2579), 452-453.
6. Bush, K.; Jacoby, G.A. Updated functional classification of betalactamases. Antimicrob. Agents. Chemother., 2010, 54(3), 969-976.
7. Bush, K. Proliferation and significance of clinically relevant betalactamases. Ann. N. Y. Acad. Sci., 2013, 1277, 84-90.
8. Richmond, M.H.; Sykes, R.B. The beta-lactamases of gramnegative bacteria and their possible physiological role. Adv. Microb. Physiol., 1973, 9, 31-88.
9. Bush, K.; Jacoby, G.A.; Medeiros, A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents. Chemother., 1995, 39(6), 1211-1233.
10. Ambler, R.P.; Coulson, A.F.; Frere, J.M.; Ghuysen, J.M.; Joris, B.; Forsman, M.; Levesque, R.C.; Tiraby, G.; Waley, S.G. A standard numbering scheme for the class A beta-lactamases. Biochem. J., 1991, 276( Pt 1), 269-270.
11. Jaurin, B.; Grundstrom, T. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of betalactamases of the penicillinase type. Proc. Natl. Acad. Sci. U. S. A., 1981, 78(8), 4897-4901.
12. Ouellette, M.; Bissonnette, L.; Roy, P.H. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 beta-lactamase gene. Proc. Natl. Acad. Sci. U. S. A., 1987, 84(21), 7378-7382.
13. Zhang, H.; Hao, Q. Crystal structure of NDM-1 reveals a common beta-lactam hydrolysis mechanism. FASEB J., 2011, 25(8), 2574-2582.
14. Knowles, J.R. Penicillin Resistance - the Chemistry of Beta- Lactamase Inhibition. Acc. Chem. Res., 1985, 18(4), 97-104.
15. English, A.R.; Retsema, J.A.; Girard, A.E.; Lynch, J.E.; Barth, W.E. CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob. Agents Chemother., 1978, 14(3), 414-419.
16. Fisher, J.; Belasco, J.G.; Charnas, R.L.; Khosla, S.; Knowles, J.R. Beta-lactamase inactivation by mechanism-based reagents. Philos. Trans. R. Soc. Lond. B Biol. Sci., 1980, 289(1036), 309-319.
17. Reading, C.; Cole, M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob. Agents Chemother., 1977, 11(5), 852-857.
18. Biondi, S.; Long, S.; Panunzio, M.; Qin, W.L. Current trends in beta-lactam based beta-lactamases inhibitors. Curr. Med. Chem., 2011, 18(27), 4223-4236.
19. Kahan, J.S.; Kahan, F.M.; Goegelman, R.; Currie, S.A.; Jackson, M.; Stapley, E.O.; Miller, T.W.; Miller, A.K.; Hendlin, D.; Mochales, S.; Hernandez, S.; Woodruff, H.B.; Birnbaum, J. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot.(Tokyo), 1979, 32(1), 1-12.
20. Sirot, D.; Chanal, C.; Bonnet, R.; De Champs, C.; Bret, L. Inhibitor-resistant TEM-33 beta-lactamase in a Shigella sonnei isolate. Antimicrob. Agents Chemother., 2001, 45(7), 2179-2180.
21. Yigit, H.; Queenan, A.M.; Rasheed, J.K.; Biddle, J.W.; Domenech-Sanchez, A.; Alberti, S.; Bush, K.; Tenover, F.C. Carbapenemresistant strain of Klebsiella oxytoca harboring carbapenemhydrolyzing beta-lactamase KPC-2. Antimicrob. Agents Chemother., 2003, 47(12), 3881-3889.
22. Paterson, D.L.; Bonomo, R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev., 2005, 18(4), 657-686.
23. Bush, K.; Fisher, J.F. Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gramnegative bacteria. Annu. Rev. Microbiol., 2011, 65, 455-478.
24. Thomson, K.S. Extended-spectrum-beta-lactamase, AmpC, and Carbapenemase issues. J. Clin. Microbiol., 2010, 48(4), 1019-1025.
25. Bush, K.; Courvalin, P.; Dantas, G.; Davies, J.; Eisenstein, B.; Huovinen, P.; Jacoby, G.A.; Kishony, R.; Kreiswirth, B.N.; Kutter, E.; Lerner, S.A.; Levy, S.; Lewis, K.; Lomovskaya, O.; Miller, J.H.; Mobashery, S.; Piddock, L.J.; Projan, S.; Thomas, C.M.; Tomasz, A.; Tulkens, P.M.; Walsh, T.R.; Watson, J.D.; Witkowski, J.; Witte, W.; Wright, G.; Yeh, P.; Zgurskaya, H.I. Tackling antibiotic resistance. Nat. Rev. Microbiol., 2011, 9(12), 894-896.
26. Brisse, S. OXY, OKP, LEN β-lactamase protein variation home page. http://www.pasteur.fr/ip/easysite/pasteur/en/research/platesformes- technologiques/pasteur-genopole-ile-de-france/genotypingof-pathogens-and-public- health-pf8/beta-lactamase-enzymevariants/ beta-lactamase-enzyme-variants.
27. Jacoby, G.A.; Bush, K. β-lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. http://www.lahey.org/Studies/.
28. Chen, Y.; Shoichet, B.; Bonnet, R. Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases. J. Am. Chem. Soc., 2005, 127(15), 5423-5434.
29. Jelsch, C.; Lenfant, F.; Masson, J.M.; Samama, J.P. Beta-lactamase TEM1 of E. coli. Crystal structure determination at 2.5 A resolution. FEBS Lett., 1992, 299(2), 135-142.
30. Jelsch, C.; Mourey, L.; Masson, J.M.; Samama, J.P. Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution. Proteins, 1993, 16(4), 364-383.
31. Kuzin, A.P.; Nukaga, M.; Nukaga, Y.; Hujer, A.M.; Bonomo, R.A.; Knox, J.R. Structure of the SHV-1 beta-lactamase. Biochemistry, 1999, 38(18), 5720-5727.
32. Matagne, A.; Frere, J.M. Contribution of mutant analysis to the understanding of enzyme catalysis: the case of class A betalactamases. Biochim. Biophys. Acta, 1995, 1246(2), 109-127.
33. Minasov, G.; Wang, X.; Shoichet, B.K. An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J. Am. Chem. Soc., 2002, 124(19), 5333-5340.
34. Nukaga, M.; Mayama, K.; Hujer, A.M.; Bonomo, R.A.; Knox, J.R. Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J. Mol. Biol., 2003, 328(1), 289-301.
35. Orencia, M.C.; Yoon, J.S.; Ness, J.E.; Stemmer, W.P.; Stevens, R.C. Predicting the emergence of antibiotic resistance by directed evolution and structural analysis. Nat. Struct. Biol., 2001, 8(3), 238-242.
36. Strynadka, N.C.; Adachi, H.; Jensen, S.E.; Johns, K.; Sielecki, A.; Betzel, C.; Sutoh, K.; James, M.N. Molecular structure of the acylenzyme intermediate in beta-lactam hydrolysis at 1.7 A resolution. Nature, 1992, 359(6397), 700-705.
37. Wang, X.; Minasov, G.; Shoichet, B.K. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol., 2002, 320(1), 85-95.
38. Wang, X.; Minasov, G.; Shoichet, B.K. Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and betalactams. Proteins, 2002, 47(1), 86-96.
39. D'Andrea, M.M.; Arena, F.; Pallecchi, L.; Rossolini, G.M. CTX-Mtype beta-lactamases: A successful story of antibiotic resistance. Int. J. Med. Microbiol., 2013.
40. Bauernfeind, A.; Grimm, H.; Schweighart, S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection, 1990, 18(5), 294-298.
41. Bonnet, R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother., 2004, 48(1), 1-14.
42. Bauernfeind, A.; Stemplinger, I.; Jungwirth, R.; Ernst, S.; Casellas, J.M. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob. Agents Chemother., 1996, 40(2), 509-513.
43. Canton, R.; Akova, M.; Carmeli, Y.; Giske, C.G.; Glupczynski, Y.; Gniadkowski, M.; Livermore, D.M.; Miriagou, V.; Naas, T.; Rossolini, G.M.; Samuelsen, O.; Seifert, H.; Woodford, N.; Nordmann, P. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect., 2012, 18(5), 413-431.
44. Canton, R.; Coque, T.M. The CTX-M beta-lactamase pandemic. Curr. Opin. Microbiol., 2006, 9(5), 466-475.
45. Livermore, D.M.; Canton, R.; Gniadkowski, M.; Nordmann, P.; Rossolini, G.M.; Arlet, G.; Ayala, J.; Coque, T.M.; Kern-Zdanowicz, I.; Luzzaro, F.; Poirel, L.; Woodford, N. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother., 2007, 59(2), 165-174.
46. Livermore, D.M.; Woodford, N. The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol., 2006, 14(9), 413-420.
47. Bush, K. Alarming beta-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae. Curr. Opin. Microbiol., 2010, 13(5), 558-564.
48. Bush, K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit. Care, 2010, 14(3), 224.
49. Chen, Y.; Delmas, J.; Sirot, J.; Shoichet, B.; Bonnet, R. Atomic resolution structures of CTX-M beta-lactamases: extended spectrum activities from increased mobility and decreased stability. J. Mol. Biol., 2005, 348(2), 349-362.
50. Ibuka, A.S.; Ishii, Y.; Galleni, M.; Ishiguro, M.; Yamaguchi, K.; Frere, J.M.; Matsuzawa, H.; Sakai, H. Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry, 2003, 42(36), 10634-10643.
51. Nichols, D.A.; Jaishankar, P.; Larson, W.; Smith, E.; Liu, G.; Beyrouthy, R.; Bonnet, R.; Renslo, A.R.; Chen, Y. Structure-based design of potent and ligand-efficient inhibitors of CTX-M class A beta-lactamase. J. Med. Chem., 2012, 55(5), 2163-2172.
52. Shoichet, B.K.; Baase, W.A.; Kuroki, R.; Matthews, B.W. A relationship between protein stability and protein function. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(2), 452-456.
53. Bethel, C.R.; Taracila, M.; Shyr, T.; Thomson, J.M.; Distler, A.M.; Hujer, K.M.; Hujer, A.M.; Endimiani, A.; Papp-Wallace, K.; Bonnet, R.; Bonomo, R.A. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems. Antimicrob. Agents Chemother., 2011, 55(7), 3465-3475.
54. Morandi, F.; Caselli, E.; Morandi, S.; Focia, P.J.; Blazquez, J.; Shoichet, B.K.; Prati, F. Nanomolar inhibitors of AmpC betalactamase. J. Am. Chem. Soc., 2003, 125(3), 685-695.
55. Carosati, E.; Sciabola, S.; Cruciani, G. Hydrogen bonding interactions of covalently bonded fluorine atoms: from crystallographic data to a new angular function in the GRID force field. J. Med. Chem., 2004, 47(21), 5114-5125.
56. Goodford, P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem., 1985, 28(7), 849-857.
57. Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J.S. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J. Chem. Inf. Model., 2007, 47(2), 279-294.
58. Molecular Discovery home page. www.moldiscovery.com
59. Chen, Y.; Shoichet, B.K. Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat. Chem. Biol., 2009, 5(5), 358-364.
60. Beharry, Z.; Chen, H.; Gadhachanda, V.R.; Buynak, J.D.; Palzkill, T. Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis. Biochem. Biophys. Res. Commun., 2004, 313(3), 541-545.
61. Lahiri, S.D.; Mangani, S.; Durand-Reville, T.; Benvenuti, M.; De Luca, F.; Sanyal, G.; Docquier, J.D. Structural Insight into Potent Broad-spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC beta-lactamases. Antimicrob. Agents Chemother., 2013, 57(6), 2496-2505.
62. Ehmann, D.E.; Jahic, H.; Ross, P.L.; Gu, R.F.; Hu, J.; Kern, G.; Walkup, G.K.; Fisher, S.L. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl. Acad. Sci. U.S.A., 2012, 109(29), 11663-11668.
63. Yigit, H.; Queenan, A.M.; Anderson, G.J.; Domenech-Sanchez, A.; Biddle, J.W.; Steward, C.D.; Alberti, S.; Bush, K.; Tenover, F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2001, 45(4), 1151-1161.
64. Villegas, M.V.; Lolans, K.; Correa, A.; Kattan, J.N.; Lopez, J.A.; Quinn, J.P.; Colombian Nosocomial Resistance Study, G. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob. Agents Chemother., 2007, 51(4), 1553-1555.
65. Nordmann, P.; Cuzon, G.; Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis., 2009, 9(4), 228-236.
66. Papp-Wallace, K.M.; Bethel, C.R.; Distler, A.M.; Kasuboski, C.; Taracila, M.; Bonomo, R.A. Inhibitor resistance in the KPC-2 betalactamase, a preeminent property of this class A beta-lactamase. Antimicrob. Agents Chemother., 2010, 54(2), 890-897.
67. Ke, W.; Bethel, C.R.; Thomson, J.M.; Bonomo, R.A.; van den Akker, F. Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. Biochemistry, 2007, 46(19), 5732-5740.
68. Ke, W.; Bethel, C.R.; Papp-Wallace, K.M.; Pagadala, S.R.; Nottingham, M.; Fernandez, D.; Buynak, J.D.; Bonomo, R.A.; van den Akker, F. Crystal structures of KPC-2 beta-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrob. Agents Chemother., 2012, 56(5), 2713-2718.
69. Padayatti, P.S.; Sheri, A.; Totir, M.A.; Helfand, M.S.; Carey, M.P.; Anderson, V.E.; Carey, P.R.; Bethel, C.R.; Bonomo, R.A.; Buynak, J.D.; van den Akker, F. Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J. Am. Chem. Soc., 2006, 128(40), 13235-13242.
70. Pasteran, F.; Mendez, T.; Guerriero, L.; Rapoport, M.; Corso, A. Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J. Clin. Microbiol., 2009, 47(6), 1631-1639.
71. Tsakris, A.; Themeli-Digalaki, K.; Poulou, A.; Vrioni, G.; Voulgari, E.; Koumaki, V.; Agodi, A.; Pournaras, S.; Sofianou, D. Comparative evaluation of combined-disk tests using different boronic acid compounds for detection of klebsiella pneumoniae carbapenemase-producing enterobacteriaceae clinical isolates. J. Clin. Microbiol., 2011, 49(8), 2804-2809.
72. Bethel, C.R.; Distler, A.M.; Ruszczycky, M.W.; Carey, M.P.; Carey, P.R.; Hujer, A.M.; Taracila, M.; Helfand, M.S.; Thomson, J.M.; Kalp, M.; Anderson, V.E.; Leonard, D.A.; Hujer, K.M.; Abe, T.; Venkatesan, A.M.; Mansour, T.S.; Bonomo, R.A. Inhibition of OXA-1 beta-lactamase by penems. Antimicrob. Agents Chemother., 2008, 52(9), 3135-3143.
73. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Ado, M.; Tsuyoshi, T.; Dos Santos, O.; Li, Z.; Francisco, G.; Lin, Y.I.; Petersen, P.J.; Yang, Y.; Weiss, W.J.; Shlaes, D.M.; Mansour, T.S. 5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of betalactamases. Bioorg. Med. Chem., 2008, 16(4), 1890-1902.
74. Hirsch, E.B.; Ledesma, K.R.; Chang, K.T.; Schwartz, M.S.; Motyl, M.R.; Tam, V.H. In vitro activity of MK-7655, a novel betalactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother., 2012, 56(7), 3753-3757.
75. Stachyra, T.; Levasseur, P.; Pechereau, M.C.; Girard, A.M.; Claudon, M.; Miossec, C.; Black, M.T. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother., 2009, 64(2), 326-329.
76. Johnson, J.W.; Gretes, M.; Goodfellow, V.J.; Marrone, L.; Heynen, M.L.; Strynadka, N.C.; Dmitrienko, G.I. Cyclobutanone analogues of beta-lactams revisited: insights into conformational requirements for inhibition of serine-and metallo-beta-lactamases. J. Am. Chem. Soc., 2010, 132(8), 2558-2560.
77. Goldstein, E.J.; Citron, D.M.; Tyrrell, K.L.; Merriam, C.V. In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine beta-lactamase inhibitor, against anaerobic bacteria. Antimicrob. Agents Chemother., 2013, 57(6), 2620-2630.
78. Livermore, D.M.; Mushtaq, S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J. Antimicrob. Chemother., 2013, 68(8), 1825-1831.
79. Jacoby, G.A. AmpC beta-lactamases. Clin. Microbiol. Rev., 2009, 22(1), 161-182, Table of Contents.
80. Pai, H.; Kang, C.I.; Byeon, J.H.; Lee, K.D.; Park, W.B.; Kim, H.B.; Kim, E.C.; Oh, M.D.; Choe, K.W. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-betalactamase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 2004, 48(10), 3720-3728.
81. Philippon, A.; Arlet, G.; Jacoby, G.A. Plasmid-determined AmpCtype beta-lactamases. Antimicrob. Agents Chemother., 2002, 46(1), 1-11.
82. Powers, R.A.; Caselli, E.; Focia, P.J.; Prati, F.; Shoichet, B.K. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design. Biochemistry, 2001, 40(31), 9207-9214.
83. Tondi, D.; Powers, R.A.; Caselli, E.; Negri, M.C.; Blazquez, J.; Costi, M.P.; Shoichet, B.K. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase. Chem. Biol., 2001, 8(6), 593-611.
84. Morosini, M.I.; Negri, M.C.; Shoichet, B.; Baquero, M.R.; Baquero, F.; Blazquez, J. An extended-spectrum AmpC-type betalactamase obtained by in vitro antibiotic selection. FEMS Microbiol. Lett., 1998, 165(1), 85-90.
85. Kiener, P.A.; Waley, S.G. Reversible inhibitors of penicillinases. Biochem. J., 1978, 169(1), 197-204.
86. Weston, G.S.; Blazquez, J.; Baquero, F.; Shoichet, B.K. Structurebased enhancement of boronic acid-based inhibitors of AmpC betalactamase. J. Med. Chem., 1998, 41(23), 4577-4586.
87. Powers, R.A.; Blazquez, J.; Weston, G.S.; Morosini, M.I.; Baquero, F.; Shoichet, B.K. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase. Protein Sci., 1999, 8(11), 2330-2337.
88. Venturelli, A.; Tondi, D.; Cancian, L.; Morandi, F.; Cannazza, G.; Segatore, B.; Prati, F.; Amicosante, G.; Shoichet, B.K.; Costi, M.P. Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J. Med. Chem., 2007, 50(23), 5644-5654.
89. Minozzi, M.; Lattanzi, G.; Benz, R.; Costi, M.P.; Venturelli, A.; Carloni, P. Permeation through the cell membrane of a boron-based beta-lactamase inhibitor. PLoS One, 2011, 6(8), e23187.
90. Caselli, E.; Powers, R.A.; Blasczcak, L.C.; Wu, C.Y.; Prati, F.; Shoichet, B.K. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases. Chem. Biol., 2001, 8(1), 17-31.
91. Eidam, O.; Romagnoli, C.; Caselli, E.; Babaoglu, K.; Pohlhaus, D.T.; Karpiak, J.; Bonnet, R.; Shoichet, B.K.; Prati, F. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as beta-lactamase inhibitors. J. Med. Chem., 2010, 53(21), 7852-7863.
92. Eidam, O.; Romagnoli, C.; Dalmasso, G.; Barelier, S.; Caselli, E.; Bonnet, R.; Shoichet, B.K.; Prati, F. Fragment-guided design of subnanomolar beta-lactamase inhibitors active in vivo. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(43), 17448-17453.
93. Tondi, D.; Morandi, F.; Bonnet, R.; Costi, M.P.; Shoichet, B.K. Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture. J. Am. Chem. Soc., 2005, 127(13), 4632-4639.
94. Tan, Q.; Ogawa, A.M.; Raghoobar, S.L.; Wisniewski, D.; Colwell, L.; Park, Y.W.; Young, K.; Hermes, J.D.; Dininno, F.P.; Hammond, M.L. Thiophenyl oxime-derived phosphonates as nanomolar class C beta-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg. Med. Chem. Lett, 2011, 21(14), 4363-4365.
95. Nishida, K.; Kunugita, C.; Uji, T.; Higashitani, F.; Hyodo, A.; Unemi, N.; Maiti, S.N.; Phillips, O.A.; Spevak, P.; Atchison, K.P.; Salama, S.M.; Atwal, H.; Micetich, R.G. In vitro and in vivo activities of Syn2190, a novel beta-lactamase inhibitor. Antimicrob. Agents Chemother., 1999, 43(8), 1895-1900.
96. Blizzard, T.A.; Chen, H.; Kim, S.; Wu, J.; Young, K.; Park, Y.W.; Ogawa, A.; Raghoobar, S.; Painter, R.E.; Hairston, N.; Lee, S.H.; Misura, A.; Felcetto, T.; Fitzgerald, P.; Sharma, N.; Lu, J.; Ha, S.; Hickey, E.; Hermes, J.; Hammond, M.L. Side chain SAR of bicyclic beta-lactamase inhibitors (BLIs). 1. Discovery of a class C BLI for combination with imipinem. Bioorg. Med. Chem. Lett., 2010, 20(3), 918-921.
97. Chen, H.; Blizzard, T.A.; Kim, S.; Wu, J.; Young, K.; Park, Y.W.; Ogawa, A.M.; Raghoobar, S.; Painter, R.E.; Wisniewski, D.; Hairston, N.; Fitzgerald, P.; Sharma, N.; Scapin, G.; Lu, J.; Hermes, J.; Hammond, M.L. Side chain SAR of bicyclic betalactamase inhibitors (BLIs). 2. N-Alkylated and open chain analogs of MK-8712. Bioorg. Med. Chem. Lett., 2011, 21(14), 4267-4270.
98. Livermore, D.M.; Chen, H.Y. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J. Antimicrob. Chemother., 1997, 40(3), 335-343.
99. Heinze-Krauss, I.; Angehrn, P.; Charnas, R.L.; Gubernator, K.; Gutknecht, E.M.; Hubschwerlen, C.; Kania, M.; Oefner, C.; Page, M.G.; Sogabe, S.; Specklin, J.L.; Winkler, F. Structure-based design of beta-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J. Med. Chem., 1998, 41(21), 3961-3971.
100. Venkatesan, A.M.; Agarwal, A.; Abe, T.; Ushirogochi, H.; Yamamura, I.; Kumagai, T.; Petersen, P.J.; Weiss, W.J.; Lenoy, E.; Yang, Y.; Shlaes, D.M.; Ryan, J.L.; Mansour, T.S. Novel imidazole substituted 6-methylidene-penems as broad-spectrum betalactamase inhibitors. Bioorg. Med. Chem., 2004, 12(22), 5807-5817.
101. Petersen, P.J.; Jones, C.H.; Venkatesan, A.M.; Bradford, P.A. Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob. Agents Chemother., 2009, 53(4), 1698-1700.
102. Paukner, S.; Hesse, L.; Prezelj, A.; Solmajer, T.; Urleb, U. In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor. Antimicrob. Agents Chemother., 2009, 53(2), 505-511.
103. Papp-Wallace, K.M.; Bethel, C.R.; Gootz, T.D.; Shang, W.; Stroh, J.; Lau, W.; McLeod, D.; Price, L.; Marfat, A.; Distler, A.; Drawz, S.M.; Chen, H.; Harry, E.; Nottingham, M.; Carey, P.R.; Buynak, J.D.; Bonomo, R.A. Inactivation of a class A and a class C betalactamase by 6beta-(hydroxymethyl)penicillanic acid sulfone. Biochem. Pharmacol., 2012, 83(4), 462-471.
104. Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother., 2012, 67(7), 1597-1606.
105. Bou, G.; Santillana, E.; Sheri, A.; Beceiro, A.; Sampson, J.M.; Kalp, M.; Bethel, C.R.; Distler, A.M.; Drawz, S.M.; Pagadala, S.R.; van den Akker, F.; Bonomo, R.A.; Romero, A.; Buynak, J.D. Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J. Am. Chem. Soc., 2010, 132(38), 13320-13331.
106. Santillana, E.; Beceiro, A.; Bou, G.; Romero, A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc. Natl. Acad. Sci. U. S. A., 2007, 104(13), 5354-5359.
107. Docquier, J.D.; Calderone, V.; De Luca, F.; Benvenuti, M.; Giuliani, F.; Bellucci, L.; Tafi, A.; Nordmann, P.; Botta, M.; Rossolini, G.M.; Mangani, S. Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem. Biol., 2009, 16(5), 540-547.
108. Golemi, D.; Maveyraud, L.; Vakulenko, S.; Samama, J.P.; Mobashery, S. Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(25), 14280-14285.
109. Cross, S.; Baroni, M.; Goracci, L.; Cruciani, G. GRID-based threedimensional pharmacophores I: FLAPpharm, a novel approach for pharmacophore elucidation. J. Chem. Inf. Model., 2012, 52(10), 2587-2598.
110. Cross, S.; Ortuso, F.; Baroni, M.; Costa, G.; Distinto, S.; Moraca, F.; Alcaro, S.; Cruciani, G. GRID-based three-dimensional pharmacophores II: PharmBench, a benchmark data set for evaluating pharmacophore elucidation methods. J. Chem. Inf. Model., 2012, 52(10), 2599-2608.
111. Sirci, F.; Goracci, L.; Rodriguez, D.; van Muijlwijk-Koezen, J.; Gutierrez-de-Teran, H.; Mannhold, R. Ligand-, structure-and pharmacophore-based molecular fingerprints: a case study on adenosine A(1), A (2A), A (2B), and A (3) receptor antagonists. J. Comput. Aided Mol. Des., 2012, 26(11), 1247-1266.
112. Drawz, S.M.; Bethel, C.R.; Doppalapudi, V.R.; Sheri, A.; Pagadala, S.R.; Hujer, A.M.; Skalweit, M.J.; Anderson, V.E.; Chen, S.G.; Buynak, J.D.; Bonomo, R.A. Penicillin sulfone inhibitors of class D beta-lactamases. Antimicrob. Agents Chemother., 2010, 54(4), 1414-1424.
113. Perumal, S.K.; Pratt, R.F. Synthesis and evaluation of ketophosph(on)ates as beta-lactamase inhibitors. J. Org. Chem., 2006, 71(13), 4778-4785.
114. Cherry, P.C.; Newall, C.E.; Watson, N.S. Preparation of 7-Oxo-4-Oxa-1-Azabicyclo[3.2.0]Hept-2-Ene System and Reversible Cleavage of Its Oxazoline Ring. J. Chem. Soc. Chem. Comm., 1978(11), 469-470.
115. Jamieson, C.E.; Lambert, P.A.; Simpson, I.N. In vitro activities of novel oxapenems, alone and in combination with ceftazidime, against gram-positive and gram-negative organisms. Antimicrob. Agents Chemother., 2003, 47(8), 2615-2618.
116. Jamieson, C.E.; Lambert, P.A.; Simpson, I.N. In vitro and in vivo activities of AM-112, a novel oxapenem. Antimicrob. Agents Chemother., 2003, 47(5), 1652-1657.
117. Tan, Q.; Ogawa, A.M.; Painter, R.E.; Park, Y.W.; Young, K.; DiNinno, F.P. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity. Bioorg. Med. Chem. Lett, 2010, 20(8), 2622-2624.
118. Coleman, K.; Griffin, D.R.; Page, J.W.; Upshon, P.A. In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob. Agents Chemother., 1989, 33(9), 1580-1587.
119. Kalp, M.; Sheri, A.; Buynak, J.D.; Bethel, C.R.; Bonomo, R.A.; Carey, P.R. Efficient inhibition of class A and class D betalactamases by Michaelis complexes. J. Biol. Chem., 2007, 282(30), 21588-21591.
120. Felici, A.; Amicosante, G. Kinetic analysis of extension of substrate specificity with Xanthomonas maltophilia, Aeromonas hydrophila, and Bacillus cereus metallo-beta-lactamases. Antimicrob. Agents Chemother., 1995, 39(1), 192-199.
121. Rasmussen, B.A.; Yang, Y.; Jacobus, N.; Bush, K. Contribution of enzymatic properties, cell permeability, and enzyme expression to microbiological activities of beta-lactams in three Bacteroides fragilis isolates that harbor a metallo-beta-lactamase gene. Antimicrob. Agents Chemother., 1994, 38(9), 2116-2120.
122. Walsh, T.R.; Toleman, M.A.; Poirel, L.; Nordmann, P. Metallobeta- lactamases: the quiet before the storm? Clin. Microbiol. Rev., 2005, 18(2), 306-325.
123. Lim, H.M.; Pene, J.J.; Shaw, R.W. Cloning, nucleotide sequence, and expression of the Bacillus cereus 5/B/6 beta-lactamase II structural gene. J. Bacteriol., 1988, 170(6), 2873-2878.
124. Walsh, T.R.; Hall, L.; Assinder, S.J.; Nichols, W.W.; Cartwright, S.J.; MacGowan, A.P.; Bennett, P.M. Sequence analysis of the L1 metallo-beta-lactamase from Xanthomonas maltophilia. Biochim. Biophys. Acta, 1994, 1218(2), 199-201.
125. Laraki, N.; Galleni, M.; Thamm, I.; Riccio, M.L.; Amicosante, G.; Frere, J.M.; Rossolini, G.M. Structure of In31, a blaIMP-containing Pseudomonas aeruginosa integron phyletically related to In5, which carries an unusual array of gene cassettes. Antimicrob. Agents Chemother., 1999, 43(4), 890-901.
126. Lauretti, L.; Riccio, M.L.; Mazzariol, A.; Cornaglia, G.; Amicosante, G.; Fontana, R.; Rossolini, G.M. Cloning and characterization of blaVIM, a new integron-borne metallo-betalactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother., 1999, 43(7), 1584-1590.
127. Cornaglia, G.; Giamarellou, H.; Rossolini, G.M. Metallo-betalactamases: a last frontier for beta-lactams? Lancet Infect. Dis., 2011, 11(5), 381-393.
128. Palzkill, T. Metallo-beta-lactamase structure and function. Ann. N. Y. Acad. Sci., 2013, 1277(1), 91-104.
129. Perez-Llarena, F.J.; Bou, G. Beta-lactamase inhibitors: the story so far. Curr. Med. Chem., 2009, 16(28), 3740-3765.
130. Stachyra, T.; Pechereau, M.C.; Bruneau, J.M.; Claudon, M.; Frere, J.M.; Miossec, C.; Coleman, K.; Black, M.T. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel nonbeta-lactam beta-lactamase inhibitor. Antimicrob. Agents Chemother., 2010, 54(12), 5132-5138.
131. Borra, P.S.; Leiros, H.K.; Ahmad, R.; Spencer, J.; Leiros, I.; Walsh, T.R.; Sundsfjord, A.; Samuelsen, O. Structural and computational investigations of VIM-7: insights into the substrate specificity of vim metallo-beta- lactamases. J. Mol. Biol., 2011, 411(1), 174-189.
132. Carfi, A.; Duee, E.; Galleni, M.; Frere, J.M.; Dideberg, O. 1.85 A resolution structure of the zinc (II) beta-lactamase from Bacillus cereus. Acta Crystallogr. D Biol. Crystallogr., 1998, 54(Pt 3), 313-323.
133. Concha, N.O.; Janson, C.A.; Rowling, P.; Pearson, S.; Cheever, C.A.; Clarke, B.P.; Lewis, C.; Galleni, M.; Frere, J.M.; Payne, D.J.; Bateson, J.H.; Abdel-Meguid, S.S. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor. Biochemistry, 2000, 39(15), 4288-4298.
134. Docquier, J.D.; Benvenuti, M.; Calderone, V.; Stoczko, M.; Menciassi, N.; Rossolini, G.M.; Mangani, S. High-resolution crystal structure of the subclass B3 metallo-beta-lactamase BJP-1: rational basis for substrate specificity and interaction with sulfonamides. Antimicrob. Agents Chemother., 2010, 54(10), 4343-4351.
135. Fabiane, S.M.; Sohi, M.K.; Wan, T.; Payne, D.J.; Bateson, J.H.; Mitchell, T.; Sutton, B.J. Crystal structure of the zinc-dependent beta-lactamase from Bacillus cereus at 1.9 A resolution: binuclear active site with features of a mononuclear enzyme. Biochemistry, 1998, 37(36), 12404-12411.
136. Ullah, J.H.; Walsh, T.R.; Taylor, I.A.; Emery, D.C.; Verma, C.S.; Gamblin, S.J.; Spencer, J. The crystal structure of the L1 metallobeta-lactamase from Stenotrophomonas maltophilia at 1.7 A resolution. J. Mol. Biol., 1998, 284(1), 125-136.
137. Wilcox, D.E. Binuclear Metallohydrolases. Chem. Rev., 1996, 96(7), 2435-2458.
138. Davies, R.B.; Abraham, E.P. Metal cofactor requirements of betalactamase II. Biochem. J., 1974, 143(1), 129-135.
139. Sabath, L.D.; Abraham, E.P. Zinc as a cofactor for cephalosporinase from Bacillus cereus 569. Biochem. J., 1966, 98(1), 11C-13C.
140. Campos-Bermudez, V.A.; Gonzalez, J.M.; Tierney, D.L.; Vila, A.J. Spectroscopic signature of a ubiquitous metal binding site in the metallo-beta-lactamase superfamily. J. Biol. Inorg. Chem., 2010, 15(8), 1209-1218.
141. Galleni, M.; Lamotte-Brasseur, J.; Rossolini, G.M.; Spencer, J.; Dideberg, O.; Frere, J.M. Standard numbering scheme for class B beta-lactamases. Antimicrob. Agents Chemother., 2001, 45(3), 660-663.
142. Carfi, A.; Pares, S.; Duee, E.; Galleni, M.; Duez, C.; Frere, J.M.; Dideberg, O. The 3-D structure of a zinc metallo-beta-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J., 1995, 14(20), 4914-4921.
143. Concha, N.O.; Rasmussen, B.A.; Bush, K.; Herzberg, O. Crystal structure of the wide-spectrum binuclear zinc beta-lactamase from Bacteroides fragilis. Structure, 1996, 4(7), 823-836.
144. Garcia-Saez, I.; Docquier, J.D.; Rossolini, G.M.; Dideberg, O. The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form. J. Mol. Biol., 2008, 375(3), 604-611.
145. Garcia-Saez, I.; Hopkins, J.; Papamicael, C.; Franceschini, N.; Amicosante, G.; Rossolini, G.M.; Galleni, M.; Frere, J.M.; Dideberg, O. The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J. Biol. Chem., 2003, 278(26), 23868-23873.
146. Murphy, T.A.; Catto, L.E.; Halford, S.E.; Hadfield, A.T.; Minor, W.; Walsh, T.R.; Spencer, J. Crystal structure of Pseudomonas aeruginosa SPM-1 provides insights into variable zinc affinity of metallo-beta-lactamases. J. Mol. Biol., 2006, 357(3), 890-903.
147. Jacquin, O.; Balbeur, D.; Damblon, C.; Marchot, P.; De Pauw, E.; Roberts, G.C.; Frere, J.M.; Matagne, A. Positively cooperative binding of zinc ions to Bacillus cereus 569/H/9 beta-lactamase II suggests that the binuclear enzyme is the only relevant form for catalysis. J. Mol. Biol., 2009, 392(5), 1278-1291.
148. Badarau, A.; Damblon, C.; Page, M.I. The activity of the dinuclear cobalt-beta-lactamase from Bacillus cereus in catalysing the hydrolysis of beta-lactams. Biochem. J., 2007, 401(1), 197-203.
149. Badarau, A.; Page, M.I. Loss of enzyme activity during turnover of the Bacillus cereus beta-lactamase catalysed hydrolysis of betalactams due to loss of zinc ion. J. Biol. Inorg. Chem., 2008, 13(6), 919-928.
150. Wommer, S.; Rival, S.; Heinz, U.; Galleni, M.; Frere, J.M.; Franceschini, N.; Amicosante, G.; Rasmussen, B.; Bauer, R.; Adolph, H.W. Substrate-activated zinc binding of metallo-beta - lactamases: physiological importance of mononuclear enzymes. J. Biol. Chem., 2002, 277(27), 24142-24147.
151. Wang, Z.; Fast, W.; Benkovic, S.J. On the mechanism of the metallo-beta-lactamase from Bacteroides fragilis. Biochemistry, 1999, 38(31), 10013-10023.
152. Wang, Z.; Fast, W.; Valentine, A.M.; Benkovic, S.J. Metallo- betalactamase: structure and mechanism. Curr. Opin. Chem. Biol., 1999, 3(5), 614-622.
153. Cozzini, P.; Kellogg, G.E.; Spyrakis, F.; Abraham, D.J.; Costantino, G.; Emerson, A.; Fanelli, F.; Gohlke, H.; Kuhn, L.A.; Morris, G.M.; Orozco, M.; Pertinhez, T.A.; Rizzi, M.; Sotriffer, C.A. Target flexibility: an emerging consideration in drug discovery and design. J. Med. Chem., 2008, 51(20), 6237-6255.
154. Malabanan, M.M.; Amyes, T.L.; Richard, J.P. A role for flexible loops in enzyme catalysis. Curr. Opin. Struct. Biol., 2010, 20(6), 702-710.
155. Qasba, P.K.; Ramakrishnan, B.; Boeggeman, E. Substrate-induced conformational changes in glycosyltransferases. Trends Biochem Sci, 2005, 30(1), 53-62.
156. Spyrakis, F.; BidonChanal, A.; Barril, X.; Luque, F.J. Protein flexibility and ligand recognition: challenges for molecular modeling. Curr. Top. Med. Chem., 2011, 11(2), 192-210.
157. Scrofani, S.D.; Chung, J.; Huntley, J.J.; Benkovic, S.J.; Wright, P.E.; Dyson, H.J. NMR characterization of the metallo-betalactamase from Bacteroides fragilis and its interaction with a tightbinding inhibitor: role of an active-site loop. Biochemistry, 1999, 38(44), 14507-14514.
158. Huntley, J.J.; Fast, W.; Benkovic, S.J.; Wright, P.E.; Dyson, H.J. Role of a solvent-exposed tryptophan in the recognition and binding of antibiotic substrates for a metallo-beta-lactamase. Protein Sci., 2003, 12(7), 1368-1375.
159. Moali, C.; Anne, C.; Lamotte-Brasseur, J.; Groslambert, S.; Devreese, B.; Van Beeumen, J.; Galleni, M.; Frere, J.M. Analysis of the importance of the metallo-beta-lactamase active site loop in substrate binding and catalysis. Chem. Biol., 2003, 10(4), 319-329.
160. Osano, E.; Arakawa, Y.; Wacharotayankun, R.; Ohta, M.; Horii, T.; Ito, H.; Yoshimura, F.; Kato, N. Molecular characterization of an enterobacterial metallo beta-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob. Agents Chemother., 1994, 38(1), 71-78.
161. Poirel, L.; Naas, T.; Nicolas, D.; Collet, L.; Bellais, S.; Cavallo, J.D.; Nordmann, P. Characterization of VIM-2, a carbapenemhydrolyzing metallo-beta-lactamase and its plasmid- and integronborne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother., 2000, 44(4), 891-897.
162. Toney, J.H.; Hammond, G.G.; Fitzgerald, P.M.; Sharma, N.; Balkovec, J.M.; Rouen, G.P.; Olson, S.H.; Hammond, M.L.; Greenlee, M.L.; Gao, Y.D. Succinic acids as potent inhibitors of plasmid-borne IMP-1 metallo-beta-lactamase. J. Biol. Chem., 2001, 276(34), 31913-31918.
163. Yamaguchi, Y.; Jin, W.; Matsunaga, K.; Ikemizu, S.; Yamagata, Y.; Wachino, J.; Shibata, N.; Arakawa, Y.; Kurosaki, H. Crystallographic investigation of the inhibition mode of a VIM-2 metallo-beta-lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor. J. Med. Chem., 2007, 50(26), 6647-6653.
164. Walter, M.; Felici, A.; Galleni, M.; Soto, R.; Adlington, R.; Baldwin, J.; Frére, J.-M.; Gololobov, M.; Schofield, C. Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamases. Bioorg. Med. Chem. Lett., 1996, 6, 2455-2458.
165. Walter, M.; Valladares, M.; Adlington, R.; Amicosante, G.; Baldwin, J.; Frére, J.-M.; Galleni, M.; Rossolini, G.M.; Schofield, C. Hydroxamate Inhibitors ofAeromonas hydrophilaAE036 Metallo-B-lactamase. Bioorg. Chem., 1999, 27(35-40).
166. Goto, M.; Takahashi, T.; Yamashita, F.; Koreeda, A.; Mori, H.; Ohta, M.; Arakawa, Y. Inhibition of the metallo-beta-lactamase produced from Serratia marcescens by thiol compounds. Biol. Pharm. Bull., 1997, 20(11), 1136-1140.
167. Kurosaki, H.; Yasuzawa, H.; Yamaguchi, Y.; Jin, W.; Arakawa, Y.; Goto, M. Detection of a metallo-beta-lactamase (IMP-1) by fluorescent probes having dansyl and thiol groups. Org. Biomol. Chem., 2003, 1(1), 17-20.
168. Bounaga, S.; Laws, A.P.; Galleni, M.; Page, M.I. The mechanism of catalysis and the inhibition of the Bacillus cereus zinc-dependent beta-lactamase. Biochem. J., 1998, 331( Pt 3), 703-711.
169. Fitzgerald, P.M.; Wu, J.K.; Toney, J.H. Unanticipated inhibition of the metallo-beta-lactamase from Bacteroides fragilis by 4-morpholineethanesulfonic acid (MES): a crystallographic study at 1.85-A resolution. Biochemistry, 1998, 37(19), 6791-6800.
170. Payne, D.J.; Bateson, J.H.; Gasson, B.C.; Khushi, T.; Proctor, D.; Pearson, S.C.; Reid, R. Inhibition of metallo-beta-lactamases by a series of thiol ester derivatives of mercaptophenylacetic acid. FEMS Microbiol. Lett., 1997, 157(1), 171-175.
171. Payne, D.J.; Du, W.; Bateson, J.H. beta-Lactamase epidemiology and the utility of established and novel beta-lactamase inhibitors. Expert Opin. Investig. Drugs, 2000, 9(2), 247-261.
172. Bounaga, S.; Galleni, M.; Laws, A.P.; Page, M.I. Cysteinyl peptide inhibitors of Bacillus cereus zinc beta-lactamase. Bioorg. Med. Chem., 2001, 9(2), 503-510.
173. Toney, J.H.; Cleary, K.A.; Hammond, G.G.; Yuan, X.; May, W.J.; Hutchins, S.M.; Ashton, W.T.; Vanderwall, D.E. Structure-activity relationships of biphenyl tetrazoles as metallo-beta-lactamase inhibitors. Bioorg. Med. Chem. Lett., 1999, 9(18), 2741-2746.
174. Toney, J.H.; Fitzgerald, P.M.; Grover-Sharma, N.; Olson, S.H.; May, W.J.; Sundelof, J.G.; Vanderwall, D.E.; Cleary, K.A.; Grant, S.K.; Wu, J.K.; Kozarich, J.W.; Pompliano, D.L.; Hammond, G.G. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase. Chem. Biol., 1998, 5(4), 185-196.
175. Nagano, R.; Adachi, Y.; Hashizume, T.; Morishima, H. In vitro antibacterial activity and mechanism of action of J-111,225, a novel 1beta-methylcarbapenem, against transferable IMP-1 metallo-beta-lactamase producers. J. Antimicrob. Chemother., 2000, 45(3), 271-276.
176. Nagano, R.; Adachi, Y.; Imamura, H.; Yamada, K.; Hashizume, T.; Morishima, H. Carbapenem derivatives as potential inhibitors of various beta-lactamases, including class B metallo-beta-lactamases. Antimicrob. Agents Chemother., 1999, 43(10), 2497-2503.
177. Payne, D.J.; Hueso-Rodriguez, J.A.; Boyd, H.; Concha, N.O.; Janson, C.A.; Gilpin, M.; Bateson, J.H.; Cheever, C.; Niconovich, N.L.; Pearson, S.; Rittenhouse, S.; Tew, D.; Diez, E.; Perez, P.; De La Fuente, J.; Rees, M.; Rivera-Sagredo, A. Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob. Agents Chemother., 2002, 46(6), 1880-1886.
178. Siemann, S.; Evanoff, D.P.; Marrone, L.; Clarke, A.J.; Viswanatha, T.; Dmitrienko, G.I. N-arylsulfonyl hydrazones as inhibitors of IMP-1 metallo-beta-lactamase. Antimicrob. Agents Chemother., 2002, 46(8), 2450-2457.
179. Quiroga, M.I.; Franceschini, N.; Rossolini, G.M.; Gutkind, G.; Bonfiglio, G.; Franchino, L.; Amicosante, G. Interaction of cefotetan and the metallo-beta-lactamases produced in Aeromonas spp. and in vitro activity. Chemotherapy, 2000, 46(3), 177-183.
180. Ishii, Y.; Eto, M.; Mano, Y.; Tateda, K.; Yamaguchi, K. In vitro potentiation of carbapenems with ME1071, a novel metallo-betalactamase inhibitor, against metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother., 2010, 54(9), 3625-3629.
181. Hiraiwa, Y.; Morinaka, A.; Fukushima, T.; Kudo, T. Metallo-betalactamase inhibitory activity of phthalic acid derivatives. Bioorg. Med. Chem. Lett., 2009, 19(17), 5162-5165.
182. Vella, P.; Hussein, W.M.; Leung, E.W.; Clayton, D.; Ollis, D.L.; Mitic, N.; Schenk, G.; McGeary, R.P. The identification of new metallo-beta-lactamase inhibitor leads from fragment-based screening. Bioorg. Med. Chem. Lett., 2011, 21(11), 3282-3285.
183. Faridoon; Hussein, W.M.; Vella, P.; Islam, N.U.; Ollis, D.L.; Schenk, G.; McGeary, R.P. 3-mercapto-1,2,4-triazoles and Nacylated thiosemicarbazides as metallo-beta-lactamase inhibitors. Bioorg. Med. Chem. Lett., 2012, 22(1), 380-386.
184. Heinz, U.; Bauer, R.; Wommer, S.; Meyer-Klaucke, W.; Papamichaels, C.; Bateson, J.; Adolph, H.W. Coordination geometries of metal ions in d-or l-captopril-inhibited metallo-betalactamases. J. Biol. Chem., 2003, 278(23), 20659-20666.
185. Mohamed, M.S.; Hussein, W.M.; McGeary, R.P.; Vella, P.; Schenk, G.; Abd El-Hameed, R.H. Synthesis and kinetic testing of new inhibitors for a metallo-beta-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Eur. J. Med. Chem., 2011, 46(12), 6075-6082.
186. Hussein, W.M.; Fatahala, S.S.; Mohamed, Z.M.; McGeary, R.P.; Schenk, G.; Ollis, D.L.; Mohamed, M.S. Synthesis and kinetic testing of tetrahydropyrimidine-2-thione and pyrrole derivatives as inhibitors of the metallo-beta-lactamase from Klebsiella pneumonia and Pseudomonas aeruginosa. Chem. Biol. Drug Des., 2012, 80(4), 500-515.
187. Kurosaki, H.; Yamaguchi, Y.; Higashi, T.; Soga, K.; Matsueda, S.; Yumoto, H.; Misumi, S.; Yamagata, Y.; Arakawa, Y.; Goto, M. Irreversible inhibition of metallo-beta-lactamase (IMP-1) by 3-(3-mercaptopropionylsulfanyl)propionic acid pentafluorophenyl ester. Angew. Chem. Int. Ed. Engl., 2005, 44(25), 3861-3864.
188. Kurosaki, H.; Yamaguchi, Y.; Yasuzawa, H.; Jin, W.; Yamagata, Y.; Arakawa, Y. Probing, inhibition, and crystallographic characterization of metallo-beta-lactamase (IMP-1) with fluorescent agents containing dansyl and thiol groups. Chem. Med. Chem., 2006, 1(9), 969-972.
189. Jin, W.; Arakawa, Y.; Yasuzawa, H.; Taki, T.; Hashiguchi, R.; Mitsutani, K.; Shoga, A.; Yamaguchi, Y.; Kurosaki, H.; Shibata, N.; Ohta, M.; Goto, M. Comparative study of the inhibition of metallo-beta-lactamases (IMP-1 and VIM-2) by thiol compounds that contain a hydrophobic group. Biol. Pharm. Bull., 2004, 27(6), 851-856.
190. Minond, D.; Saldanha, S.A.; Subramaniam, P.; Spaargaren, M.; Spicer, T.; Fotsing, J.R.; Weide, T.; Fokin, V.V.; Sharpless, K.B.; Galleni, M.; Bebrone, C.; Lassaux, P.; Hodder, P. Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries. Bioorg. Med. Chem., 2009, 17(14), 5027-5037.
191. Weide, T.; Saldanha, S.A.; Minond, D.; Spicer, T.P.; Fotsing, J.R.; Spaargaren, M.; Frere, J.M.; Bebrone, C.; Sharpless, K.B.; Hodder, P.S.; Fokin, V.V. NH-1,2,3-Triazole-based Inhibitors of the VIM-2 Metallo-beta-Lactamase: Synthesis and Structure-Activity Studies. ACS Med. Chem. Lett., 2010, 1(4), 150-154.
192. Yong, D.; Toleman, M.A.; Giske, C.G.; Cho, H.S.; Sundman, K.; Lee, K.; Walsh, T.R. Characterization of a new metallo-betalactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother., 2009, 53(12), 5046-5054.
193. Nordmann, P.; Poirel, L.; Walsh, T.R.; Livermore, D.M. The emerging NDM carbapenemases. Trends Microbiol., 2011, 19(12), 588-595.
194. Walsh, T.R.; Weeks, J.; Livermore, D.M.; Toleman, M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis., 2011, 11(5), 355-362.
195. Kumarasamy, K.K.; Toleman, M.A.; Walsh, T.R.; Bagaria, J.; Butt, F.; Balakrishnan, R.; Chaudhary, U.; Doumith, M.; Giske, C.G.; Irfan, S.; Krishnan, P.; Kumar, A.V.; Maharjan, S.; Mushtaq, S.; Noorie, T.; Paterson, D.L.; Pearson, A.; Perry, C.; Pike, R.; Rao, B.; Ray, U.; Sarma, J.B.; Sharma, M.; Sheridan, E.; Thirunarayan, M.A.; Turton, J.; Upadhyay, S.; Warner, M.; Welfare, W.; Livermore, D.M.; Woodford, N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis., 2010, 10(9), 597-602.
196. Hsu, L.Y.; Koh, T.H. World Health Day 2011: combating antimicrobial resistance. Singapore Med. J., 2011, 52(4), 230-231.
197. McKenna, M. The enemy within. Sci. Am., 2011, 304(4), 46-53.
198. Materon, I.C.; Beharry, Z.; Huang, W.; Perez, C.; Palzkill, T. Analysis of the context dependent sequence requirements of active site residues in the metallo-beta-lactamase IMP-1. J. Mol. Biol., 2004, 344(3), 653-663.
199. King, D.T.; Worrall, L.J.; Gruninger, R.; Strynadka, N.C. New Delhi metallo-beta-lactamase: structural insights into beta-lactam recognition and inhibition. J. Am. Chem. Soc., 2012, 134(28), 11362-11365.
200. Antony, J.; Gresh, N.; Olsen, L.; Hemmingsen, L.; Schofield, C.J.; Bauer, R. Binding of D- and L-captopril inhibitors to metallo-betalactamase studied by polarizable molecular mechanics and quantum mechanics. J. Comput. Chem., 2002, 23(13), 1281-1296.
201. Yuan, Q.; He, L.; Ke, H. A potential substrate binding conformation of beta-lactams and insight into the broad spectrum of NDM-1 activity. Antimicrob. Agents Chemother., 2012, 56(10), 5157-5163.
202. Chen, Y.; Bonnet, R.; Shoichet, B.K. The acylation mechanism of CTX-M beta-lactamase at 0.88 a resolution. J. Am. Chem. Soc., 2007, 129(17), 5378-5380.
203. Delmas, J.; Leyssene, D.; Dubois, D.; Birck, C.; Vazeille, E.; Robin, F.; Bonnet, R. Structural insights into substrate recognition and product expulsion in CTX-M enzymes. J. Mol. Biol., 2010, 400(1), 108-120.
204. Petrella, S.; Ziental-Gelus, N.; Mayer, C.; Renard, M.; Jarlier, V.; Sougakoff, W. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob. Agents Chemother., 2008, 52(10), 3725-3736.
205. Hanes, M.S.; Jude, K.M.; Berger, J.M.; Bonomo, R.A.; Handel, T.M. Structural and biochemical characterization of the interaction between KPC-2 beta-lactamase and beta-lactamase inhibitor protein. Biochemistry, 2009, 48(39), 9185-9193.
206. Usher, K.; Blaszczak, L.; Weston, G.; Shoichet, B.; Remington, S. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry, 1998, 37, 16082-16092.
207. Patera, A.; Blaszczak, L.; Shoichet, B.K. Crystal Structures of Substrate and Inhibitor Complexes with AmpC -Lactamase: Possible Implications for Substrate-Assisted Catalysis. J. Am. Chem. Soc., 2000, 122, 10504-10512.
208. Beadle, B.M.; Trehan, I.; Focia, P.J.; Shoichet, B.K. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase. Structure, 2002, 10(3), 413-424.
209. Powers, R.A.; Morandi, F.; Shoichet, B.K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC betalactamase. Structure, 2002, 10(7), 1013-1023.
210. Powers, R.A.; Shoichet, B.K. Structure-based approach for binding site identification on AmpC beta-lactamase. J. Med. Chem., 2002, 45(15), 3222-3234.
211. Trehan, I.; Morandi, F.; Blaszczak, L.C.; Shoichet, B.K. Using steric hindrance to design new inhibitors of class C betalactamases. Chem. Biol., 2002, 9(9), 971-980.
212. Beadle, B.M.; Shoichet, B.K. Structural basis for imipenem inhibition of class C beta-lactamases. Antimicrob. Agents Chemother., 2002, 46(12), 3978-3980.
213. Babaoglu, K.; Shoichet, B.K. Deconstructing fragment-based inhibitor discovery. Nat. Chem. Biol., 2006, 2(12), 720-723.
214. Wyrembak, P.N.; Babaoglu, K.; Pelto, R.B.; Shoichet, B.K.; Pratt, R.F. O-aryloxycarbonyl hydroxamates: new beta-lactamase inhibitors that cross-link the active site. J. Am. Chem. Soc., 2007, 129(31), 9548-9549.
215. Morandi, S.; Morandi, F.; Caselli, E.; Shoichet, B.K.; Prati, F. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. Bioorg. Med. Chem., 2008, 16(3), 1195-1205.
216. Babaoglu, K.; Simeonov, A.; Irwin, J.J.; Nelson, M.E.; Feng, B.; Thomas, C.J.; Cancian, L.; Costi, M.P.; Maltby, D.A.; Jadhav, A.; Inglese, J.; Austin, C.P.; Shoichet, B.K. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J. Med. Chem., 2008, 51(8), 2502-2511.
217. Teotico, D.G.; Babaoglu, K.; Rocklin, G.J.; Ferreira, R.S.; Giannetti, A.M.; Shoichet, B.K. Docking for fragment inhibitors of AmpC beta-lactamase. Proc. Natl. Acad. Sci. U.S.A., 2009, 106(18), 7455-7460.
218. Tondi, D.; Calo, S.; Shoichet, B.K.; Costi, M.P. Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(11), 3416-3419.
219. Trehan, I.; Beadle, B.M.; Shoichet, B.K. Inhibition of AmpC betalactamase through a destabilizing interaction in the active site. Biochemistry, 2001, 40(27), 7992-7999.
220. Beadle, B.M.; Shoichet, B.K. Structural bases of stability-function tradeoffs in enzymes. J. Mol. Biol., 2002, 321(2), 285-296.
221. Meroueh, S.O.; Minasov, G.; Lee, W.; Shoichet, B.K.; Mobashery, S. Structural aspects for evolution of beta-lactamases from penicillin-binding proteins. J. Am. Chem. Soc., 2003, 125(32), 9612-9618.
222. Roth, T.A.; Minasov, G.; Morandi, S.; Prati, F.; Shoichet, B.K. Thermodynamic cycle analysis and inhibitor design against betalactamase. Biochemistry, 2003, 42(49), 14483-14491.
223. Chen, Y.; Minasov, G.; Roth, T.A.; Prati, F.; Shoichet, B.K. The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J. Am. Chem. Soc., 2006, 128(9), 2970-2976.
224. Chen, Y.; McReynolds, A.; Shoichet, B.K. Re-examining the role of Lys67 in class C beta-lactamase catalysis. Protein Sci., 2009, 18(3), 662-669.
225. Thomas, V.L.; McReynolds, A.C.; Shoichet, B.K. Structural bases for stability-function tradeoffs in antibiotic resistance. J. Mol. Biol., 2010, 396(1), 47-59.
226. Sun, T.; Nukaga, M.; Mayama, K.; Braswell, E.H.; Knox, J.R. Comparison of beta-lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci., 2003, 12(1), 82-91.
227. Schneider, K.D.; Karpen, M.E.; Bonomo, R.A.; Leonard, D.A.; Powers, R.A. The 1.4 A crystal structure of the class D betalactamase OXA-1 complexed with doripenem. Biochemistry, 2009, 48(50), 11840-11847.
228. Paetzel, M.; Danel, F.; de Castro, L.; Mosimann, S.C.; Page, M.G.; Strynadka, N.C. Crystal structure of the class D beta-lactamase OXA-10. Nat. Struct. Biol., 2000, 7(10), 918-925.
229. Golemi, D.; Maveyraud, L.; Vakulenko, S.; Tranier, S.; Ishiwata, A.; Kotra, L.P.; Samama, J.P.; Mobashery, S. The First Structural and Mechanistic Insights for Class D beta-Lactamases: Evidence for a Novel Catalytic Process for Turnover of beta-Lactam Antibiotics. J. Am. Chem. Soc., 2000, 122, 6132-6133.
230. Maveyraud, L.; Golemi, D.; Kotra, L.P.; Tranier, S.; Vakulenko, S.; Mobashery, S.; Samama, J.P. Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure, 2000, 8(12), 1289-1298.
231. Baurin, S.; Vercheval, L.; Bouillenne, F.; Falzone, C.; Brans, A.; Jacquamet, L.; Ferrer, J.L.; Sauvage, E.; Dehareng, D.; Frere, J.M.; Charlier, P.; Galleni, M.; Kerff, F. Critical role of tryptophan 154 for the activity and stability of class D beta-lactamases. Biochemistry, 2009, 48(47), 11252-11263.
232. Vercheval, L.; Bauvois, C.; di Paolo, A.; Borel, F.; Ferrer, J.L.; Sauvage, E.; Matagne, A.; Frere, J.M.; Charlier, P.; Galleni, M.; Kerff, F. Three factors that modulate the activity of class D betalactamases and interfere with the post-translational carboxylation of Lys70. Biochem. J., 2010, 432(3), 495-504.
233. Pernot, L.; Frenois, F.; Rybkine, T.; L'Hermite, G.; Petrella, S.; Delettre, J.; Jarlier, V.; Collatz, E.; Sougakoff, W. Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem. J. Mol. Biol., 2001, 310(4), 859-874.
234. Smith, C.A.; Antunes, N.T.; Stewart, N.K.; Toth, M.; Kumarasiri, M.; Chang, M.; Mobashery, S.; Vakulenko, S.B. Structural Basis for Carbapenemase Activity of the OXA-23 beta-Lactamase from Acinetobacter baumannii. Chem. Biol., 2013, 20(9), 1107-1115.
235. Kaitany, K.C.; Klinger, N.V.; June, C.M.; Ramey, M.E.; Bonomo, R.A.; Powers, R.A.; Leonard, D.A. Structures of the Class D Carbapenemases OXA-23 and OXA-146: Mechanistic Basis of Activity against Carbapenems, Extended-Spectrum Cephalosporins, and Aztreonam. Antimicrob. Agents Chemother., 2013, 57(10), 4848-4855.
236. Schneider, K.D.; Ortega, C.J.; Renck, N.A.; Bonomo, R.A.; Powers, R.A.; Leonard, D.A. Structures of the class D carbapenemase OXA-24 from Acinetobacter baumannii in complex with doripenem. J. Mol. Biol., 2011, 406(4), 583-594.
237. Docquier, J.D.; Benvenuti, M.; Calderone, V.; Giuliani, F.; Kapetis, D.; De Luca, F.; Rossolini, G.M.; Mangani, S. Crystal structure of the narrow-spectrum OXA-46 class D beta-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob. Agents Chemother., 2010, 54(5), 2167-2174.
238. Yamaguchi, Y.; Kuroki, T.; Yasuzawa, H.; Higashi, T.; Jin, W.; Kawanami, A.; Yamagata, Y.; Arakawa, Y.; Goto, M.; Kurosaki, H. Probing the role of Asp-120(81) of metallo-beta-lactamase (IMP-1) by site-directed mutagenesis, kinetic studies, and X-ray crystallography. J. Biol. Chem., 2005, 280(21), 20824-20832.
239. Horton, L.B.; Shanker, S.; Mikulski, R.; Brown, N.G.; Phillips, K.J.; Lykissa, E.; Venkataram Prasad, B.V.; Palzkill, T. Mutagenesis of zinc ligand residue Cys221 reveals plasticity in the IMP-1 metallo-beta-lactamase active site. Antimicrob. Agents Chemother., 2012, 56(11), 5667-5677.
240. Lassaux, P.; Hamel, M.; Gulea, M.; Delbruck, H.; Mercuri, P.S.; Horsfall, L.; Dehareng, D.; Kupper, M.; Frere, J.M.; Hoffmann, K.; Galleni, M.; Bebrone, C. Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J. Med. Chem., 2010, 53(13), 4862-4876.
241. Lassaux, P.; Traore, D.A.; Loisel, E.; Favier, A.; Docquier, J.D.; Sohier, J.S.; Laurent, C.; Bebrone, C.; Frere, J.M.; Ferrer, J.L.; Galleni, M. Biochemical and structural characterization of the subclass B1 metallo-beta-lactamase VIM-4. Antimicrob. Agents Chemother., 2011, 55(3), 1248-1255.
242. Kim, Y.; Tesar, C.; Mire, J.; Jedrzejczak, R.; Binkowski, A.; Babnigg, G.; Sacchettini, J.; Joachimiak, A. Structure of apo- and monometalated forms of NDM-1 - a highly potent carbapenemhydrolyzing metallo-beta-lactamase. PLoS One, 2011, 6(9), e24621.
243. Green, V.L.; Verma, A.; Owens, R.J.; Phillips, S.E.; Carr, S.B. Structure of New Delhi metallo-beta-lactamase 1 (NDM-1). Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun., 2011, 67(Pt 10), 1160-1164.
244. King, D.; Strynadka, N. Crystal structure of New Delhi metallobeta- lactamase reveals molecular basis for antibiotic resistance. Protein Sci., 2011, 20(9), 1484-1491.
245. Guo, Y.; Wang, J.; Niu, G.; Shui, W.; Sun, Y.; Zhou, H.; Zhang, Y.; Yang, C.; Lou, Z.; Rao, Z. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug. Protein Cell., 2011, 2(5), 384-394.
246. Balderas-Renteria, I.; Gonzalez-Barranco, P.; Garcia, A.; Banik, B.K.; Rivera, G. Anticancer drug design using scaffolds of β- lactams, sulfonamides, quinoline, quinoxaline and natural products. Drugs advances in clinical trials. Curr. Med. Chem., 2012, 19(26), 4377-4398.